TACC3 and urinary bladder cancer: FGFR3–TACC3 fusions have been described in different tumor types, including glioma, lung cancer, bladder cancer, head and neck squamous cancer, lung squamous cell carcinoma, and cervical cancer [26,27,30,31,38,42,43].